Marcelo Basso Gazzana

TL;DR: In this paper, the authors compared the efficacy and safety of therapeutic versus prophylactic anticoagulation in patients hospitalised with COVID-19 in 31 sites in Brazil, and found that in the case of stable patients, in-hospital oral rivaroxaban (20 mg or 15 mg daily) or initial subcutaneous enoxaparin (1 mg/kg twice per day) or intravenous unfractionated heparin (to achieve a 0·3-0·7 IU/mL anti-Xa concentration) for clinically unstable patients, followed

TL;DR: Patients with PAH exhibit a unique microbiome profile that has the high predictive potential for PAH, which highlights previously unknown roles of gut bacteria in this disease and could lead to new therapeutic, diagnostic, or management paradigms forPAH.

TL;DR: A high mortality rate is found in TB patients requiring intensive care, especially in those with an early ICU admission and early intensive care unit admission, independently associated with the in-hospital mortality.

TL;DR: A high overall mortality rate for patients hospitalized with TB in a region with a high prevalence of TB and HIV is found, unlikely to be explained only by the HIV epidemic.

TL;DR: So far no pharmacological intervention was proven effective and safe to warrant its use in the routine treatment of COVID-19 patients, so such patients should ideally be treated in the context of clinical trials.